{"id":19939,"date":"2019-03-18T12:37:38","date_gmt":"2019-03-18T12:37:38","guid":{"rendered":"https:\/\/positivelysharing.wordpress.com\/?p=19939"},"modified":"2019-03-18T12:37:38","modified_gmt":"2019-03-18T12:37:38","slug":"cytodyn-submits-first-part-of-biologics-license-application-to-fda-for-flagship-hiv-drug-leronlimab","status":"publish","type":"post","link":"https:\/\/positivelysharing.org\/blog\/2019\/03\/18\/cytodyn-submits-first-part-of-biologics-license-application-to-fda-for-flagship-hiv-drug-leronlimab\/","title":{"rendered":"CytoDyn submits first part of biologics license application to FDA for flagship HIV drug leronlimab"},"content":{"rendered":"<span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Reading Time: <\/span> <span class=\"rt-time\"> &lt; 1<\/span> <span class=\"rt-label rt-postfix\">minute<\/span><\/span><p><img decoding=\"async\" src=\"https:\/\/static1.proactiveinvestors.com\/thumbs\/upload\/Article\/Image\/2019_03\/757z468_1552910054_shutterstock_275603264.jpg\" alt=\"A researcher in a lab\" \/><\/p>\n<p><a class=\"companyPopupTrigger\" href=\"https:\/\/www.proactiveinvestors.com\/OTCMKTS:CYDY\/CytoDyn\/\" rel=\"11906\">CytoDyn<\/a>\u00a0Inc (<a class=\"companyPopupTrigger\" href=\"https:\/\/www.proactiveinvestors.com\/OTCMKTS:CYDY\/CytoDyn\/\" rel=\"11906\">OTCMKTS:CYDY<\/a>), a Vancouver-based biotech announced Monday that it has filed the non-clinical portion of a Biologics License Application for its flagship leronlimab (PRO 140) as a combination therapy for HIV using the US Food and Drug Administration (FDA)\u2019s rolling review process.\u00a0 <a href=\"https:\/\/www.proactiveinvestors.com\/companies\/news\/216644\/cytodyn-submits-first-part-of-biologics-license-application-to-fda-for-flagship-hiv-drug-leronlimab-216644.html\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p><span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Reading Time: <\/span> <span class=\"rt-time\"> &lt; 1<\/span> <span class=\"rt-label rt-postfix\">minute<\/span><\/span>CytoDyn\u00a0Inc (OTCMKTS:CYDY), a Vancouver-based biotech announced Monday that it has filed the non-clinical portion of a Biologics License Application for its flagship&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":{"0":"post-19939","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-hiv"},"jetpack_featured_media_url":"","amp_enabled":true,"_links":{"self":[{"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/posts\/19939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/comments?post=19939"}],"version-history":[{"count":0,"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/posts\/19939\/revisions"}],"wp:attachment":[{"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/media?parent=19939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/categories?post=19939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/tags?post=19939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}